64.70 +0.08 (0.12%)
After hours: 6:56PM EST
|Bid||64.50 x 1800|
|Ask||64.85 x 1100|
|Day's range||63.30 - 64.75|
|52-week range||56.56 - 85.97|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||659.39|
|Forward dividend & yield||2.84 (4.49%)|
|Ex-dividend date||12 Mar 2021|
|1y target est||N/A|
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. The acquisition provides Gilead with Hepcludex® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020.
Diodes Incorporated (Nasdaq: DIOD), today announced Brett Whitmire, Chief Financial Officer; Emily Yang, Sr. Vice President of Worldwide Sales and Marketing; and Laura Mehrl, Director of Investor Relations, will participate in the Loop Capital Markets Virtual Consumer, Industrials & TMT Conference on Thursday, March 11, 2021. Management will be available throughout the day to host conference calls with investors participating in the event.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s HIV, hepatitis C virus (HCV), and COVID-19 research and development programs at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021) taking place from March 6-10. The breadth of data at the meeting reflects Gilead’s longstanding commitment to applying its scientific innovation toward addressing some of the world’s most challenging viruses and advancing global health.